Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis

Currently, endocrine therapy is the standard treatment for hormone receptor-positive advanced breast cancer (ABC). Despite the high sensitivity of anti-estrogen therapy, many breast cancer patients still experience disease progression, relapse, and reduced overall survival (OS) because of endocrine...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Liang, Jiang, Weifan, Li, Wenwei, Guo, Chungen, Luo, Lihua, Gao, Yufeng, Cao, Yali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353490/
https://www.ncbi.nlm.nih.gov/pubmed/35949321
http://dx.doi.org/10.3892/etm.2022.11512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353490/
https://www.ncbi.nlm.nih.gov/pubmed/35949321
http://dx.doi.org/10.3892/etm.2022.11512

Ejemplares similares